← IMMUNIC, INC. (IMUX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
IMMUNIC, INC. (IMUX)
Pharmaceutical Preparations · market cap $134M · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Immunic, Inc. (IMUX) is a clinical-stage pharmaceutical company with a market cap of ~$201M and a single meaningful asset: IMU-838 (vidofludimus calcium), an oral small-molecule in Phase 3 development for relapsing-remitting multiple sclerosis (RRMS). The company carries $186.6M in cash against zero revenue, implying a ~32-month runway and a modest net enterprise value relative to peers at this stage.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
- 2026-12-31Phase 3imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| IMU-838 tablets | Phase 3 | Multiple Sclerosis, Relapsing-Remitting |
| IMU-838 (30 mg/day) | Phase 2 | Relapsing-Remitting Multiple Sclerosis (RRMS) |
| IMU-838 | Phase 3 | Multiple Sclerosis |
Price & technical context
3-month
-41.6%
6-month
-24.9%
12-month
-2.0%
52-wk range
$5.10–$16.90
vs 50-day MA
-35.1%
vs 200-day MA
-23.8%
Realized vol
79.9%
Max drawdown
-73.8%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IMUX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.